Sarepta slides further after it reverses course and says it will stop shipments of gene therapy
announced Monday evening that it would stop shipments of its gene treatment per a request from the US Food and Drug Administration, a reversal from its earlier stance doubling-down on continuing to se...
Sarepta slips further after it says it will keep selling gene therapy despite FDA’s request to pull it
slipped about 5% on Monday after the drugmaker said it would continue selling its gene treatment despite a request from the US Food and Drug Administration to pull the therapy from the market. Sarepta...
Sarepta dives on reports that FDA will ask it to stop selling gene treatment
The Food and Drug Administration will request to stop all shipments of its most lucrative drug after it disclosed last month that a second patient receiving its experimental gene therapy died of live...
Johnson & Johnson pops on top- and bottom-line beat, boost to full-year outlook
shares are the top performer in the S&P 500 on Wednesday morning, jumping nearly 6% after the drugmaker posted better-than-expected earnings and hiked its outlook for the year. Revenue hit $23.7 billi...
Hims jumps after announcing plans to offer generic Wegovy in Canada in 2026
rose after the company announced that it will expand to Canada next year, offering generic versions of blockbuster weight-loss shot, Wegovy. Novo’s patent on semaglutide, the active ingredient in its...
Eli Lilly is fattening its stockpiles of GLP-1s to prevent tariffs from trimming its profits
As the threat of tariffs looms over the pharmaceutical industry, it appears isn’t taking any chances with its top revenue driver. As of May of this year, the US has imported nearly 3x as many peptide...
Moderna rises, reaching highest price since March
is up more than 11% on seemingly no news beyond positive trial data for its experimental flu vaccine over a week ago. The company, which still makes most of its revenue from declining COVID-19 vaccine...
Moderna rises after positive flu vaccine trial results, paving way for combo shot
rose more than 5% in premarket trading after announcing positive results for its experimental flu vaccine, paving the way for a combination COVID-19 immunization. The company’s mRNA-based flu shot was...
.jpg?w=1600&auto=compress%2Cformat&cs=srgb)
Hims recovers some of its losses after filling out C-suite
rose more than 10% Friday morning after the company revealed a new addition to its C-suite, cutting some of the losses following a messy breakup with . Hims announced Thursday that it hired Dheerja Ka...
Novo pairs up with Weight Watchers after dumping Hims
announced Thursday that it’s pairing up with to distribute its blockbuster weight-loss shot, which comes days after a similar partnership with imploded . Novo has been looking for ways to spark sales...
Hims & Hers on track for biggest drop ever after Novo Nordisk ends partnership
stock plunged, on track for its biggest single-day drop ever, after said it was ending its relatively new partnership with the telehealth company, citing concerns about what it called Hims’ “illegal m...
Eli Lilly slips after UK declines to cover Alzheimer’s drug
fell about 3% on Friday after the United Kingdom’s national health provider said it wouldn’t cover the company’s new Alzheimer’s treatment. The benefits of the injection are too small to justify the ...
Gilead wins approval for twice yearly HIV prevention shot
won approval from the Food and Drug Administration to market a twice yearly injection that prevents HIV in high-risk patients, potentially helping bring the AIDS pandemic to heel and cushioning the co...
Sarepta tumbles after second patient death from gene therapy treatment
is down nearly 40% in premarket trading after the company disclosed over the weekend that a second patient receiving its experimental gene therapy died of liver failure. The company said Sunday that i...
The controversial rise of Franken-pills: Telehealth companies push to mix meds in a single pill
When it comes to erectile dysfunction pills, telehealth companies are blurring the line between medicine and marketing. In an effort to differentiate themselves and retain customers, companies like , ...
Eli Lilly insists its telehealth partners must “follow the law” after CFO comments confused industry watchers
says the telehealth providers it partners with must "follow the law" when it comes to compounding, following its chief financial officer's statements from earlier this week that confused industry watc...
Tempus AI CEO on the “insanely large” AI healthcare opportunity
has only been public for a year. But it’s a been a big, volatile year. And its big swings — it’s been up as much 120% and down by nearly 40% at times — have put it on the radar screen of some retail ...
Eli Lilly’s telehealth deals require platforms to stop compounding GLP-1s, CFO says
deals with telehealth companies to sell cheaper versions of its popular weight-loss drug Zepbound come with a caveat: the telehealth companies cannot sell compounded versions of its GLP-1 drug, nor it...
Obesity treatment startup Metsera rises on positive trial results
New York-based obesity treatment startup is up by double digits after it reported encouraging results from early trials of a drug candidate. Metsera’s drug, MET-233, helped patients shed up to 8.4% o...
Tempus AI jumps after hit from short seller’s report
Shares of , an unprofitable vendor of cancer screening tests that also licenses data for use in drug discovery, soared on Monday, erasing much of the loss it suffered after a short seller released a s...